-
公开(公告)号：KR1020090039038A
公开(公告)日：2009-04-22
申请号：KR1020070104435
申请日：2007-10-17
Applicant: 한국화학연구원
IPC: C07D209/90 , A61K31/403 , A61P35/00
CPC classification number: C07D491/04
Abstract: A phenanthrene lactam derivative having the anticancer activity is provided to prevent and treat cancer and disease with excellent anticancer activity. A phenanthrene lactam derivative having chemical formula 1 is produced by reaction of the compound of chemical formula 2 and the compound of chemical formula 3 in a solution. R1, R2, R3, R4, R5, R6 and R7R is hydrogen, halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy or aryloxy. R4 and R5, R5 and R6, or R6 and R7 forms dioxol. R8 is the hydrogen or the C1-6 alkyl. The composite for preventing caner and pharmaceutical treatment comprises the phenanthrene lactam derivative of chemical formula 1 or pharmaceutically allowable salt.
Abstract translation: 提供具有抗癌活性的菲内酰胺衍生物，以预防和治疗具有优异抗癌活性的癌症和疾病。 具有化学式1的菲内酰胺衍生物通过化学式2的化合物和化学式3的化合物在溶液中的反应来制备。 R1，R2，R3，R4，R5，R6和R7R是氢，卤素，羟基，C1-6烷基，C1-6烷氧基或芳氧基。 R4和R5，R5和R6，或R6和R7形成二氧杂环戊烯。 R8是氢或C1-6烷基。 用于预防癌症和药物治疗的复合物包括化学式1的菲内酰胺衍生物或药学上可允许的盐。
-
公开(公告)号：KR100651650B1
公开(公告)日：2006-11-30
申请号：KR1020000060039
申请日：2000-10-12
Applicant: 한국화학연구원
CPC classification number: C07D493/08 , A61K31/37 , A61K36/23 , C07D311/16 , A61K2300/00
Abstract: 본 발명은 유효성분으로서 아위(Ferulae Resina)로부터 분리된 세스키테르펜(sesquiterpene) 화합물인 갈바닉산, 카라타비시놀, 움벨리프레논, 파네시페롤 B, 파네시페롤 C 및 이들의 혼합물로 이루어진 그룹으로부터 선택된 어느 하나를 약제학적으로 허용되는 담체와 함께 함유하는 항암제 조성물에 관한 것으로, 본 발명의 조성물은 폐암, 난소암, 흑색종, 중추신경계 종양, 결장암, 백혈병 등 각종 악성종양의 예방 및 치료제로 사용될 수 있다.
-
Patent Agency Ranking
公开(公告)号：KR1020040014023A
公开(公告)日：2004-02-14
申请号：KR1020020047189
申请日：2002-08-09
Applicant: 한국화학연구원
IPC: C07D405/12
CPC classification number: C07D405/12
Abstract: PURPOSE: Benzopyran derivatives substituted by secondary amine containing imidazole and a method for preparing the same are provided. The compounds are useful for treatment of cancer, diabetic retinopathy and external brain wound. CONSTITUTION: Benzopyran derivatives substituted by secondary amine containing imidazole represented by the formula(1), partial stereo isomers thereof and pharmaceutically acceptable salts thereof are provided, wherein R1 is H, CN, NO2 or NH2; R2 is CH3, CHORaRa or CHOOZ; Ra is C1-C4 linear or branched chain alkyl; Z is C2-C6 linear or branched chain alkyl; R3 and R4 are independently H, Cl, Br, F, C1-C3 linear or branched chain alkyl, ORb, CF3, OCF3, NO2 or CO2Rb; Rb is H or C1-C3 alkyl; and * is chiral carbon. A method for preparing the compound of the formula(I) comprises reacting epoxide compounds of the formula(II) with imidazole containing secondary amine compounds of the formula(III) in the presence of metal salt and a solvent, wherein the metal salt is selected from Mg(ClO4)2, COCl2, LiClO4, NaClO4, CaCl2, ZnCl2, LiBF4 and Zn(Tf)2; and the solvent is selected from acetonitrile, tetrahydrofuran and dimethylformamide.
Abstract translation: 目的：提供由含仲胺的咪唑取代的苯并吡喃衍生物及其制备方法。 该化合物可用于治疗癌症，糖尿病性视网膜病变和外部脑部伤口。 构成：提供由式（1）表示的含仲胺的咪唑取代的苯并吡喃衍生物，其部分立体异构体及其药学上可接受的盐，其中R1为H，CN，NO2或NH2; R2是CH3，CHORaRa或CHOOZ; Ra是C1-C4直链或支链烷基; Z是C 2 -C 6直链或支链烷基; R 3和R 4独立地为H，Cl，Br，F，C 1 -C 3直链或支链烷基，ORb，CF 3，OCF 3，NO 2或CO 2 R b; Rb是H或C 1 -C 3烷基; 和*是手性碳。 制备式（I）化合物的方法包括在金属盐和溶剂的存在下使式（II）的环氧化合物与含有式（III）的仲胺化合物的咪唑反应，其中选择金属盐 从Mg（ClO4）2，COCl2，LiClO4，NaClO4，CaCl2，ZnCl2，LiBF4和Zn（Tf）2; 溶剂选自乙腈，四氢呋喃和二甲基甲酰胺。
-
公开(公告)号：KR1020030005787A
公开(公告)日：2003-01-23
申请号：KR1020010041239
申请日：2001-07-10
Applicant: 한국화학연구원
IPC: A61K31/165
Abstract: PURPOSE: A pharmaceutical composition containing myxochelin-A which exhibits excellent anticancer activity against human cancer cells, together with excellent antioxidant activity as a main component is provided which can be effectively used as an effective antioxidant and anticancer agent. CONSTITUTION: The pharmaceutical composition contains myxochelin-A of formula 1 obtained by being separated from myxobacteria or being chemically synthesized or semisynthesized. The myxochelin-A is purely separated by the steps of: separating a biomass and absorption resin by culturing Angiococcus disciformis strains as myxobacteria in the presence of absorption resin and centrifuging a culture solution; adding an organic solvent, preferably a mixed solvent of acetone and methanol; extracting and filtering to remove the biomass and absorption resin; preparing an active fraction by concentrating the filtrate under reduced pressure and extracting a crude extract in an organic solvent; and successively performing silica gel liquid chromatography and recycling preparative HPLC.
Abstract translation: 目的：提供能够有效地用作有效的抗氧化剂和抗癌剂的含有对人类癌细胞具有优异抗癌活性的粘液素-A的药物组合物，以及优异的抗氧化活性为主要成分。 构成：药物组合物含有通过与粘液细菌分离或化学合成或半合成获得的式1的粘液素-A。 通过以下步骤纯化粘液素-A：通过在吸收树脂存在下培养球状球形细菌菌株作为粘液细菌分离生物质和吸收树脂并离心培养液; 加入有机溶剂，优选丙酮和甲醇的混合溶剂; 提取和过滤除去生物质和吸收树脂; 通过减压浓缩滤液并在有机溶剂中萃取粗提取物制备活性级分; 并依次进行硅胶液相色谱和再循环制备型HPLC。
-
公开(公告)号：KR1020010047127A
公开(公告)日：2001-06-15
申请号：KR1019990051200
申请日：1999-11-18
Applicant: 한국화학연구원
IPC: A61K31/425
Abstract: PURPOSE: An anticancer drug containing a compound KR-15012 is provided, which has anticancer activity better than or equal to doxorubicin and excellent anticancer effect against cancer cell strains exhibiting resistance to conventional anticancer drugs such as doxorubicin and cisplatin. CONSTITUTION: An anticancer drug containing a compound KR-15012 represented by the formula 1 or salts thereof. The anticancer drug exhibits excellent anticancer effect against a cancer cell selected from the group consisting of A-549, SK-OV-3, SK-MEL-2, XF498 and HCT15, DCT15/ADM, A2780 and CP70.
Abstract translation: 目的：提供含有化合物KR-15012的抗癌药物，其具有优于或等于多柔比星的抗癌活性，并且对抗多种抗癌药物如多柔比星和顺铂的癌细胞株具有优异的抗癌作用。 构成：含有式1化合物KR-15012或其盐的抗癌药。 抗癌药对选自A-549，SK-OV-3，SK-MEL-2，XF498和HCT15，DCT15 / ADM，A2780和CP70的癌细胞表现出优异的抗癌作用。
-
96.发明公开4'-오-데메틸-에피포도필로톡신-베타-디-글루코시드의새로운아세탈유도체,이의제조방법및이를포함하는항암제조성물 失效新型缩醛衍生物4'-o-demethyl-epi-grape pilotoxin-beta-di-glucoside及其制备方法和含有它们的抗癌组合物
-
-
-
-
-
-
Search Results
97
records
(took 0.024 seconds)
